BACKGROUND: Mutations of @entity470 ( @entity470 ) in @entity1149 ( @entity1149 ) predict longer @entity1349 ( @entity1349 ) and response to @entity470 @entity4149 kinase inhibitors (TKIs). The clinical relevance of different mutations in terms of response to TKIs and prognosis is still unclear. OBJECTIVES: The aims of the present study were to assess the relationship between mutations in exon 18, 19 and 21 in @entity1 treated with TKIs and their clinical outcomes, and evaluate the role of specific point mutations. METHODS: We included in this analysis 55 @entity1 with metastatic @entity1149 and mutations in exon 18, 19 and 21, treated in our center between 2004 and 2014. All @entity1 received treatment with TKIs in first and/or subsequent lines. Endpoints analyzed were @entity1349 (primary) and @entity1054 ( @entity1054 ) (secondary), according to exon mutations and specific point mutations. RESULTS: A strong negative prognostic association for @entity1349 (p  =  0.02) and @entity1054 (p  =  0.03) was found for exon 18 mutations compared with exon 19 deletions . A trend toward a longer median @entity1349 was observed in exon 19 deletions versus exon 21 point mutations (+6.6  months), although more exon 19-mutated @entity1 had brain metastases at diagnosis. Comparing each mutation, @entity61083 and @entity68915 of exon 19 and @entity9512 mutation of exon 21, a trend toward improved @entity1349 in @entity61083 was found. CONCLUSION: In this analysis, exon 19 deletions were associated with better outcomes, despite a higher percentage of brain metastases in this group. The prognostic relevance of @entity61083 requires further studies.

Different XXXX Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in @entity1149 : A Single Institution Analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity9512 :: ('p|SUB|L|858|R', 'ProteinMutation') :: ['p.L858R'] @entity61083 :: ('p|DEL|746,750|A', 'ProteinMutation') :: ['p.E746_A750del'] @entity68915 :: ('p|DEL|746,751|T', 'ProteinMutation') :: ['p.E746_T751del'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['TTP', 'time to progression'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity470 :: (1956,Gene) :: ['EGFR']
